NASDAQ:JAGX Jaguar Health (JAGX) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free JAGX Stock Alerts $0.17 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.16▼$0.1850-Day Range$0.06▼$0.1852-Week Range$0.05▼$1.22Volume19.25 million shsAverage Volume50.68 million shsMarket Capitalization$46.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Jaguar Health alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Jaguar Health Stock (NASDAQ:JAGX)Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Read More JAGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAGX Stock News HeadlinesApril 22, 2024 | americanbankingnews.comJaguar Health (NASDAQ:JAGX) Now Covered by StockNews.comApril 17, 2024 | msn.comWhy Jaguar Health Stock Is Up TodayApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 17, 2024 | markets.businessinsider.comGold Moves Higher; Morgan Stanley Earnings Top ViewsApril 16, 2024 | investorplace.comWhy Is Jaguar Health (JAGX) Stock Up 44% Today?April 10, 2024 | benzinga.comS&P 500 Down 1%; Delta Air Lines Posts Upbeat EarningsApril 10, 2024 | msn.comJaguar Health shareholders approve reverse stock splitApril 10, 2024 | investorplace.comWhat Is Going on With Jaguar Health (JAGX) Stock Today?April 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 10, 2024 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of StockholdersApril 9, 2024 | msn.comWhy Jaguar Health Stock Is Soaring After-HoursApril 3, 2024 | finance.yahoo.comJaguar Health Full Year 2023 Earnings: US$1.79 loss per share (vs US$36.18 loss in FY 2022)April 2, 2024 | finance.yahoo.comJaguar Health, Inc. (NASDAQ:JAGX) Q4 2023 Earnings Call TranscriptApril 1, 2024 | investorplace.comJAGX Stock Earnings: Jaguar Health Misses Revenue for Q4 2023April 1, 2024 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Reports 2023 Financial ResultsMarch 31, 2024 | markets.businessinsider.comWhat Wall Street expects from Jaguar Health's earningsMarch 20, 2024 | edition.cnn.comJaguar Health, Inc.March 20, 2024 | finance.yahoo.comGEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to MarketMarch 15, 2024 | finance.yahoo.comCapricor Therapeutics, Inc. (4LN2.F)March 1, 2024 | msn.comWhat In The World Is Going On With Jaguar Health (JAGX) Stock?February 23, 2024 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Requests and Receives Hearing on Nasdaq Listing ComplianceFebruary 17, 2024 | money.usnews.comJaguar Health IncFebruary 15, 2024 | finance.yahoo.comJaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in DogsFebruary 14, 2024 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct ReliefFebruary 14, 2024 | finance.yahoo.comJaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct ReliefFebruary 12, 2024 | ca.finance.yahoo.comJaguar Health, Inc. (JAGX)February 12, 2024 | finance.yahoo.comJaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related DiarrheaSee More Headlines Receive JAGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/17/2021Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:JAGX CUSIPN/A CIK1585608 Webwww.jaguaranimalhealth.com Phone(415) 371-8300FaxN/AEmployees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,300,000.00 Net Margins-423.11% Pretax Margin-429.27% Return on Equity-837.11% Return on Assets-80.76% Debt Debt-to-Equity Ratio6.33 Current Ratio2.00 Quick Ratio1.34 Sales & Book Value Annual Sales$9.76 million Price / Sales4.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book2.43Miscellaneous Outstanding Shares276,220,000Free Float275,774,000Market Cap$46.96 million OptionableNo Data Beta1.35 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMs. Lisa A. Conte (Age 65)Founder, CEO, President & Director Comp: $771.4kDr. Pravin R. Chaturvedi Ph.D. (Age 61)Chief Scientific Officer & Chair of Scientific Advisory Board Comp: $539.04kMr. Jonathan S. Wolin CPA (Age 61)J.D., M.B.A., Chief of Staff, Chief Compliance Officer & General Counsel Comp: $520.29kMr. Ian H. Wendt M.B.A. (Age 56)Chief Commercial Officer Comp: $441.31kDr. Steven R. King Ph.D. (Age 66)Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary Comp: $477.66kMs. Carol R. Lizak M.B.A. (Age 60)Chief Financial Officer Mr. Peter HodgeSenior Director of Investor Relations, Business Development & Special EventsDr. Karen J. Brunke Ph.D. (Age 71)Executive VP of Corporate & Business Development Mr. David SesinChief Manufacturing OfficerDr. Massimo Radaelli M.B.A. (Age 66)Ph.D., President of Jaguar International More ExecutivesKey CompetitorsNabriva TherapeuticsNASDAQ:NBRVAadi BioscienceNASDAQ:AADIImmuneeringNASDAQ:IMRXRockwell MedicalNASDAQ:RMTICalciMedicaNASDAQ:CALCView All Competitors JAGX Stock Analysis - Frequently Asked Questions How have JAGX shares performed in 2024? Jaguar Health's stock was trading at $0.1514 at the beginning of 2024. Since then, JAGX shares have increased by 12.3% and is now trading at $0.17. View the best growth stocks for 2024 here. Are investors shorting Jaguar Health? Jaguar Health saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 14,360,000 shares, a decline of 27.1% from the March 31st total of 19,710,000 shares. Based on an average daily trading volume, of 59,870,000 shares, the days-to-cover ratio is currently 0.2 days. View Jaguar Health's Short Interest. When is Jaguar Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our JAGX earnings forecast. How were Jaguar Health's earnings last quarter? Jaguar Health, Inc. (NASDAQ:JAGX) released its quarterly earnings data on Wednesday, November, 17th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.09. The biotechnology company had revenue of $0.63 million for the quarter. Jaguar Health had a negative trailing twelve-month return on equity of 837.11% and a negative net margin of 423.11%. During the same period in the previous year, the firm posted ($0.63) EPS. When did Jaguar Health's stock split? Jaguar Health's stock reverse split on Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September 8th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 8th 2021. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. What other stocks do shareholders of Jaguar Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT). When did Jaguar Health IPO? Jaguar Health (JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers. How do I buy shares of Jaguar Health? Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JAGX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jaguar Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
